Overview

The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1

Status:
Not yet recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) compared to insertion 1-day post-op.
Phase:
Phase 4
Details
Lead Sponsor:
Grene Vision Group
Collaborator:
Ocular Therapeutix, Inc.
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate